BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

CytImmune Sciences Inc.'s CYT-6091 Anti-Tumor Nanotherapeutic To Begin Testing In A Phase I Clinical Trial


5/31/2006 5:40:39 PM

CytImmune Sciences Inc., an early clinical stage nano-medicine company focused on the development and targeted delivery of multifunctional anti- cancer therapeutics, announced today it has received notification from the FDA to commence a Phase I clinical trial to evaluate the safety, pharmacokinetics and clinical benefit of its lead drug candidate, CYT-6091, a TNF-bearing pegylated colloidal gold nanoparticle, in patients with advanced cancer. Up to 42 patients with advanced cancer whose disease has failed to respond to existing therapies or where no approved therapy is available may be enrolled in the study. The intravenously administered, dose- escalation study will be conducted at the National Cancer Institute (NCI) in Bethesda, Md.

Read at News OK

News OK
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->